Applied Molecular Transport to Present at Upcoming November Investor Conferences

Rhea-AI Summary

Applied Molecular Transport Inc. (Nasdaq: AMTI) will participate in two upcoming investor conferences. The first event is the Guggenheim 4th Annual Immunology and Neurology Day on November 14, 2022, at 9:35 a.m. ET in New York, presented by CEO Tahir Mahmood. The second is the Jefferies London Healthcare Conference on November 16, 2022, at 1:30 p.m. GMT, featuring COO Shawn Cross and CMO Bittoo Kanwar. Live webcasts will be available on their website, with archived replays for 30 days.

AMT focuses on developing novel oral biologic products leveraging its technology platform.

SOUTH SAN FRANCISCO, Calif., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a clinical-stage biopharmaceutical company, today announced its participation at the following investor conferences:

Event: Guggenheim 4^th Annual Immunology and Neurology Day
Format: Corporate Presentation
Date & Time: Monday, November 14, 2022, at 9:35 a.m. ET
Location: New York, New York
Presenter: Tahir Mahmood, Ph.D., chief executive officer and co-founder

Event: Jefferies London Healthcare Conference
Format: Fireside Chat
Date & Time:   Wednesday, November 16, 2022, at 1:30 p.m. GMT
Location: London, UK
Presenters: Shawn Cross, president and chief operating officer, and Bittoo Kanwar, M.D., chief medical officer

Live webcasts will be accessible via the Events page of the Applied Molecular Transport website at https://ir.appliedmt.com/news-events/events. Archived replays will be available for 30 days following the events.

About Applied Molecular Transport Inc.

AMT is a clinical-stage biopharmaceutical company developing novel oral biologic product candidates, by leveraging its technology platform to design biologic product candidates in patient friendly oral dosage forms. AMT’s product candidates are designed to precisely target the relevant pathophysiology of disease. AMT’s proprietary technology platform is incorporated in its product candidates, exploiting existing natural cellular trafficking pathways to drive the active transport of diverse therapeutic modalities across the IE barrier. Active transport is an efficient mechanism that utilizes the cell’s own machinery to transport materials across the IE barrier.

AMT’s headquarters, internal GMP manufacturing and lab facilities are located in South San Francisco, CA. For additional information on AMT, please visit www.appliedmt.com.

Investor Relations Contact:
Andrew Chang
Head, Investor Relations & Corporate Communications
achang@appliedmt.com

Media Contacts:
Alexandra Santos
Wheelhouse Life Science Advisors
asantos@wheelhouselsa.com

Aljanae Reynolds
Wheelhouse Life Science Advisors
areynolds@wheelhouselsa.com

FAQ

What is Applied Molecular Transport Inc. (AMTI) participating in?

Applied Molecular Transport Inc. (AMTI) is participating in the Guggenheim 4th Annual Immunology and Neurology Day and the Jefferies London Healthcare Conference.

When is the Guggenheim 4th Annual Immunology and Neurology Day event?

The Guggenheim 4th Annual Immunology and Neurology Day event is on November 14, 2022, at 9:35 a.m. ET.

Who will present at the Jefferies London Healthcare Conference?

Shawn Cross, president and COO, and Bittoo Kanwar, M.D., chief medical officer, will present at the Jefferies London Healthcare Conference.

Where can I watch the Applied Molecular Transport Inc. webcasts?

You can watch the webcasts on the Events page of Applied Molecular Transport's website.

What is the focus of Applied Molecular Transport Inc. (AMTI)?

Applied Molecular Transport Inc. (AMTI) focuses on developing novel oral biologic product candidates using its proprietary technology platform.